Core Insights - Propanc Biopharma, Inc. is developing PRP, a proenzyme therapy aimed at disrupting the pancreatic cancer treatment market, which is valued at over $3 billion and has a low five-year survival rate of 13% [1][2] Company Overview - Propanc Biopharma, Inc. focuses on creating novel treatments for chronic diseases, particularly recurrent and metastatic cancer [3] - The company is advancing PRP towards clinical development for advanced solid tumors, prioritizing pancreatic and ovarian cancers [2] Product Development - PRP has shown over 85% tumor growth inhibition in preclinical pancreatic models [5] - The therapy targets cancer stem cells, aiming to prevent recurrence and metastasis by addressing the underlying drivers of cancer proliferation [3][5] - PRP is designed to sensitize resistant tumors to standard chemotherapy, potentially offering higher efficacy with lower toxicity [5] Clinical Trials - Phase 1b First-In-Human trials for PRP are scheduled for 2026, with a $100 million facility in place to support development [2]